We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
(+14%)
Cap. Flow
-$244M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19
Avg Time Held Equity + Options
7.6
quarters
Top 10 Avg Time Held Equity + Options
6.2
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
8
quarters
Top 10 Avg Time Held Equity only
6.2
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$95.5M |
| 2 |
Viking Therapeutics
VKTX
|
+$57.4M |
| 3 |
argenx
ARGX
|
+$52.2M |
| 4 |
Adagio Medical Holdings
ADGM
|
+$46.7M |
| 5 |
Oruka Therapeutics
ORKA
|
+$43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$441M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$74.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$60M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$38.8M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$35.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.6% |
| 2 | Miscellaneous | 1.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
VRNA
76
CALL
DELISTED
Verona Pharma
VRNA
| $7.19M | 0.15% |
+250,000
| New | +$6.15M |
2024 Q3
0 quarters
|
|
|
VRNA
77
PUT
DELISTED
Verona Pharma
VRNA
| $7.19M | 0.15% |
+250,000
| New | +$6.15M |
2024 Q3
0 quarters
|
|
78
Amylyx Pharmaceuticals
AMLX
$3.4B
| $6.89M | 0.15% |
+2,125,649
| New | +$4.78M |
2024 Q3
0 quarters
|
|
79
Bicycle Therapeutics
BCYC
$250M
| $5.79M | 0.12% |
255,994
-316,006
| -55% | -$7.29M |
2024 Q2
1 quarter
|
|
80
Veru
VERU
$37.5M
| $5.6M | 0.12% |
728,316
+21,988
| +3% | +$190K |
2018 Q3
24 quarters
|
|
81
PUT
Filana Therapeutics
FLNA
$35.1M
| $5.39M | 0.11% |
183,000
| – | – |
2024 Q2
1 quarter
|
|
82
CALL
Fulcrum Therapeutics
FULC
$282M
| $5.36M | 0.11% |
+1,500,000
| New | +$11.1M |
2024 Q3
0 quarters
|
|
83
BridgeBio Oncology
BBOT
$237M
| $5.22M | 0.11% |
500,000
| – | – |
2024 Q1
2 quarters
|
|
84
Biodesix
BDSX
$256M
| $3.87M | 0.08% |
108,694
| – | – |
2024 Q2
1 quarter
|
|
85
Precision BioSciences
DTIL
$166M
| $3.82M | 0.08% |
426,293
| – | – |
2024 Q1
2 quarters
|
|
86
Mereo BioPharma
MREO
$48.3M
| $3.35M | 0.07% |
815,722
-437,528
| -35% | -$1.81M |
2024 Q2
1 quarter
|
|
87
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $3.28M | 0.07% |
255,151
| – | – |
2020 Q2
17 quarters
|
|
88
Nanobiotix
NBTX
$1.08B
| $3.19M | 0.07% |
555,066
| – | – |
2020 Q4
15 quarters
|
|
89
Absci
ABSI
$1.52B
| $2.67M | 0.06% |
700,000
| – | – |
2024 Q1
2 quarters
|
|
90
LeonaBio Inc
LONA
$58.6M
| $2.41M | 0.05% |
540,296
| – | – |
2020 Q3
16 quarters
|
|
91
X4 Pharmaceuticals
XFOR
$246M
| $2.37M | 0.05% |
118,182
| – | – |
2023 Q1
6 quarters
|
|
92
enVVeno Medical
NVNO
$5.38M
| $2.33M | 0.05% |
19,838
+2,029
| +11% | +$373K |
2021 Q4
11 quarters
|
|
93
Kymera Therapeutics
KYMR
$8.86B
| $2.19M | 0.05% |
+46,213
| New | +$2.04M |
2024 Q3
0 quarters
|
|
|
TRIB
94
Trinity Biotech
TRIB
$5.81M
| $1.98M | 0.04% |
60,000
| – | – |
2024 Q1
2 quarters
|
|
95
Pyxis Oncology
PYXS
$155M
| $1.87M | 0.04% |
+508,462
| New | +$1.78M |
2024 Q3
0 quarters
|
|
96
iRhythm Holdings
IRTC
$3.5B
| $1.68M | 0.04% |
22,591
-12,614
| -36% | -$1M |
2024 Q1
2 quarters
|
|
97
Structure Therapeutics
GPCR
$1.57B
| $1.53M | 0.03% |
34,852
| – | – |
2024 Q2
1 quarter
|
|
98
Lexeo Therapeutics
LXEO
$217M
| $1.26M | 0.03% |
+139,835
| New | +$1.67M |
2024 Q3
0 quarters
|
|
99
PUT
Novavax
NVAX
$2.11B
| $1.26M | 0.03% |
100,000
| – | – |
2023 Q3
4 quarters
|
|
100
Fate Therapeutics
FATE
$234M
| $1.21M | 0.03% |
345,575
| – | – |
2024 Q2
1 quarter
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $244M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.
- Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
- Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
- Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
- Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
- Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
- Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
- Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.
Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.